Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) has announced its strategic entry into the U.S. market through a manufacturing partnership with DolCas Biotech LLC, a New Jersey-based nutraceutical manufacturer. The company will begin production at GMP-certified facilities in the United States, marking a significant expansion beyond its European operations.

This strategic move aims to mitigate tariff exposure and cross-border logistical risks while enhancing production control. The partnership leverages DolCas's expertise in clinically validated formulations and vertically integrated manufacturing, strengthening Cosmos Health's position in the premium nutraceuticals space.

Positive

• Strategic entry into the U.S. market through local manufacturing partnership
• Mitigation of tariff exposure and cross-border logistical risks
• Enhanced production control through GMP-certified facilities
• Access to DolCas's expertise in clinically validated formulations

Negative

• None.

Insights

Supply Chain & Manufacturing Expert

Cosmos Health's US manufacturing launch mitigates tariff risks and strengthens supply chain resilience while enabling market expansion.

Cosmos Health's strategic agreement with DolCas Biotech represents a significant operational advancement in the company's global manufacturing footprint. By establishing production in GMP-certified facilities in the United States, Cosmos is implementing a dual-continent manufacturing strategy that addresses several critical business vulnerabilities.

The move creates meaningful tariff avoidance for US-bound products. With increasing global trade tensions and unpredictable tariff policies, domestic manufacturing provides a strategic hedge against cross-border cost uncertainties. This positions Cosmos to maintain more stable pricing and margins in the US market regardless of potential trade policy shifts.

Beyond tariffs, this arrangement delivers substantial supply chain resilience benefits. By manufacturing closer to end markets, Cosmos can reduce lead times, minimize inventory carrying costs, and respond more nimbly to demand fluctuations. The dual-manufacturing capability also provides business continuity protection against regional disruptions that could affect either European or US operations.

The partnership with DolCas Biotech gives Cosmos access to established GMP-certified infrastructure without the capital expenditure of building new facilities. This capital-efficient approach to manufacturing expansion allows faster market entry while preserving financial flexibility. The vertically integrated capabilities of DolCas also suggest potential for streamlined production processes and quality control advantages.

Healthcare Market Strategist

The US nutraceuticals market entry strategy Cosmos is executing addresses a critical market access gap in their global portfolio. The US represents the world's largest nutraceutical market, with distinctive regulatory, competitive, and consumer preference characteristics that differ significantly from European markets.

This partnership delivers three competitive advantages. First, local manufacturing credentials resonate with US consumers increasingly concerned about product origins. The "Made in America" positioning provides marketing differentiation against imported alternatives. Second, access to clinically validated formulations through DolCas aligns with the growing US consumer demand for evidence-backed supplements rather than merely traditional remedies. Third, vertically integrated production enables better quality control and potential cost efficiencies.

The strategy appears designed to position Cosmos in the premium segment of the US nutraceutical market rather than competing on price alone. By emphasizing clinical validation and quality manufacturing, Cosmos is targeting higher-margin opportunities within the competitive US supplement landscape.

DolCas Biotech's expressed enthusiasm for expanding the collaboration suggests potential for accelerated product development beyond initial manufacturing arrangements. This could enable Cosmos to rapidly expand its US product portfolio with innovations specifically tailored to American consumer preferences and regulatory requirements, potentially creating additional revenue streams beyond their existing product lineup.

CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC (“DolCas”), a New Jersey-based developer and manufacturer of clinically studied nutraceutical ingredients.

Cosmos Health is set to commence production in the United States at GMP-certified (Good Manufacturing Practice) facilities, marking a significant milestone in the Company’s operational expansion. This move not only mitigates tariff exposure and cross-border logistical risks but also enhances production control beyond its existing European footprint, positioning Cosmos to scale efficiently in the global healthcare market.

The agreement strengthens Cosmos Health’s position in the premium nutraceuticals space and supports its broader strategy to expand its portfolio with scientifically backed, high-efficacy ingredients, while also leveraging DolCas’s expertise in clinically validated formulations and vertically integrated manufacturing.

K. Gnaneshwar Rao, CEO at DolCas Biotech, commented: “We are thrilled to partner with Cosmos and are eager to build on this collaboration with a wide range of innovative products that will benefit both companies. Cosmos, under the visionary leadership of CEO Greg Siokas, has built an impressive portfolio of brands and products. His forward-thinking approach aligns perfectly with our values and ambitions. We see this as the beginning of a strong, strategic partnership and look forward to supporting Cosmos’ continued growth in the United States and globally.”

Greg Siokas, CEO of Cosmos Health, stated: “We are proud to reach this important milestone as we commence production in the United States through our agreement with DolCas Biotech, a partner widely recognized for its commitment to quality and innovation. This strategic move strengthens our supply chain, enhances production oversight, and positions Cosmos for scalable global growth. It also reduces exposure to tariff-related risks, adding resilience amid shifting trade dynamics.”

About DolCas Biotech LLC
DolCas Biotech LLC is a U.S.-based developer and marketer of branded, science-backed nutraceutical ingredients, founded in 2007 as an extension of Orcas Naturals founded in 1993. Its portfolio includes, among others, clinically supported products such as Curcugen® (turmeric), Ginfort® (ginger), Morikol® (marine collagen), and TruOliv® (olive polyphenols). Through its dedicated manufacturing arm in India, the company maintains full vertical integration and strict control over ingredient quality. Its facilities are GMP-certified, FDA-registered, and UL-audited, underscoring a strong commitment to regulatory excellence and product integrity.

About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com

FAQ

What is the new manufacturing partnership announced by Cosmos Health (NASDAQ:COSM)?

Cosmos Health has partnered with DolCas Biotech LLC, a New Jersey-based manufacturer, to commence production of healthcare products in GMP-certified facilities in the United States.

How will the U.S. manufacturing agreement benefit Cosmos Health (COSM)?

The agreement will help mitigate tariff exposure, reduce cross-border logistical risks, enhance production control, and support the company's expansion in the U.S. market.

Who is DolCas Biotech and what do they bring to the Cosmos Health partnership?

DolCas Biotech is a New Jersey-based developer and manufacturer of clinically studied nutraceutical ingredients, bringing expertise in clinically validated formulations and vertically integrated manufacturing.

What is the strategic significance of Cosmos Health's U.S. market entry?

The entry strengthens Cosmos Health's supply chain resilience, enhances production oversight beyond its European footprint, and positions the company for scalable global growth while reducing tariff-related risks.